Company & Sponsor Intelligence
Novartis
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials15
Recruiting0
Completed14
Countries5
Therapeutic footprint
adhdalzheimersepilepsymultiple_sclerosisneuromuscularparkinsons
Indexed studies
NCT00232050Study of Omalizumab in Moderate to Severe Bronchial Asthma
epilepsy · PHASE3
epilepsy · PHASE3
NCT00141063Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT00409708Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE2
adhd · United StatesPHASE2
NCT00481676Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
epilepsy · GermanyPHASE2
epilepsy · GermanyPHASE2
NCT00355134Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT00275912Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
epilepsy · RussiaPHASE4
epilepsy · RussiaPHASE4
NCT00956410To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
alzheimers · FrancePHASE2
alzheimers · FrancePHASE2
NCT00428389Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00561392Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
alzheimers · GermanyPHASE4
alzheimers · GermanyPHASE4
NCT00143026Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
parkinsons · AustraliaPHASE4
parkinsons · AustraliaPHASE4
NCT01023685To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT06632730Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
neuromuscular · United StatesCOMPLETED
neuromuscular · United StatesCOMPLETED
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →